Healthcare provider profile · identity verified

Divya Makin, MD

Internal Medicine · RANCHO CORDOVA, CA · NPI 1487726139

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	412	131
Amlodipine Besylate	Amlodipine Besylate	302	93
Levothyroxine Sodium	Levothyroxine Sodium	240	66
Losartan Potassium	Losartan Potassium	223	70
Hydrochlorothiazide	Hydrochlorothiazide	189	62
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	130	28
Gabapentin	Gabapentin	95	36
Lisinopril	Lisinopril	95	34
Atenolol	Atenolol	92	31
Albuterol Sulfate Hfa	Albuterol Sulfate	91	43
Pantoprazole Sodium	Pantoprazole Sodium	91	32
Omeprazole	Omeprazole	87	35
Fluticasone Propionate	Fluticasone Propionate	84	29
Famotidine	Famotidine	83	30
Metoprolol Succinate	Metoprolol Succinate	82	29
Metformin Hcl	Metformin Hcl	74	21
Duloxetine Hcl	Duloxetine Hcl	72	25
Furosemide	Furosemide	67	25
Metformin Hcl Er	Metformin Hcl	66	23
Simvastatin	Simvastatin	66	22
Potassium Chloride	Potassium Chloride	64	25
Montelukast Sodium	Montelukast Sodium	59	20
Sertraline Hcl	Sertraline Hcl	59	19
Wixela Inhub	Fluticasone Propion/Salmeterol	57	suppressed
Alendronate Sodium	Alendronate Sodium	56	15
Metoprolol Tartrate	Metoprolol Tartrate	55	18
Breyna	Budesonide/Formoterol Fumarate	48	17
Tamsulosin Hcl	Tamsulosin Hcl	45	16
Meloxicam	Meloxicam	44	20
Spiriva Respimat	Tiotropium Bromide	44	suppressed
Trazodone Hcl	Trazodone Hcl	44	16
Rosuvastatin Calcium	Rosuvastatin Calcium	43	16
Alvesco	Ciclesonide	42	14
Allopurinol	Allopurinol	40	13
Citalopram Hbr	Citalopram Hydrobromide	40	13
Clobetasol Propionate	Clobetasol Propionate	39	20
Ibuprofen	Ibuprofen	37	17
Cefadroxil	Cefadroxil	36	30
Glipizide	Glipizide	36	14
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	36	12
Prednisone	Prednisone	34	25
Veo Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	33	12
Nabumetone	Nabumetone	32	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	32	suppressed
Clonazepam	Clonazepam	30	suppressed
Donepezil Hcl	Donepezil Hcl	30	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	29	suppressed
Baclofen	Baclofen	28	13
Jardiance	Empagliflozin	28	suppressed
Oxycodone Hcl	Oxycodone Hcl	25	suppressed
Pravastatin Sodium	Pravastatin Sodium	24	suppressed
Spironolactone	Spironolactone	24	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	23	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	23	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	22	13
Clopidogrel	Clopidogrel Bisulfate	21	suppressed
Chlorthalidone	Chlorthalidone	20	suppressed
Mirtazapine	Mirtazapine	20	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	19	suppressed
Humulin N	Insulin Nph Human Isophane	19	suppressed
Lorazepam	Lorazepam	19	11
Terazosin Hcl	Terazosin Hcl	19	suppressed
Estradiol	Estradiol	18	12
Ozempic	Semaglutide	18	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	17	suppressed
Varenicline Tartrate	Varenicline Tartrate	16	suppressed
Bisoprolol-Hydrochlorothiazide	Bisoprolol/Hydrochlorothiazide	15	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	15	suppressed
Warfarin Sodium	Warfarin Sodium	15	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	14	suppressed
Tramadol Hcl	Tramadol Hcl	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	12
Azithromycin	Azithromycin	13	13
Bupropion Hcl Sr	Bupropion Hcl	13	suppressed
Carvedilol	Carvedilol	13	suppressed
Fenofibrate	Fenofibrate	13	suppressed
Naproxen	Naproxen	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Pimecrolimus	Pimecrolimus	11	suppressed
Ultra-Fine Nano Pen Needle	Pen Needle, Diabetic	11	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	11	suppressed
Victoza 2-Pak	Liraglutide	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error